Literature DB >> 26722456

Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma.

Chaoyang Zhu1, Jinxing Wei1, Xin Tian2, Yang Li2, Xiaodong Li2.   

Abstract

OBJECTIVE: To explore association of peroxisome proliferator-activated receptor gamma (PPAR-γ) and phosphatase and tensin homolog (PTEN) expressions with prognosis of renal cell carcinoma (RCC).
METHODS: Our study subjects included 87 RCC tissues, 28 paracarcinoma tissues and 21 normal renal tissues. PPAR-γ and PTEN detection was conducted using immunohistochemistry staining. The association of PPAR-γ and PTEN with the clinical parameters and prognosis of RCC was analyzed. Kaplan-Meier method and Cox's proportional hazards regression model were used for exploring the relation between variables and prognosis.
RESULTS: Among normal renal tissues, para-carcinoma tissues and renal cell carcinomas, positive PPAR-γ expression presented with a progressive tendency (P < 0.001), while positive PTEN expression a degressive tendency (P < 0.001). PPAR-γ expressions were closely related to tumor size, clinical stage and lymph node metastases (all P < 0.05). PTEN expressions were in close association with tumor size, Fuhrman grading, lymph node metastases (all P < 0.05). PPAR-γ expressions were in a negative relation with PTEN expressions (r = -0.417, P < 0.001). Negative PPAR-γ expressions confer a significantly higher overall survival rate than positive PPAR-γ expressions (P = 0.015), while negative PTEN expressions confer a significantly lower overall survival rate than positive PTEN expressions (P = 0.003). Clinical staging, Fuhrman grading, lymph node metastases, PPAR-γ and PTEN were independent prognostic factors for prognosis (all P < 0.05).
CONCLUSION: PPAR-γ and PTEN expressions are related to the clinical parameters and prognosis of RCC and may be a biomarker for prognosis of RCC.

Entities:  

Keywords:  PPAR-gamma; PTEN; prognosis; renal cell carcinoma; survival

Mesh:

Substances:

Year:  2015        PMID: 26722456      PMCID: PMC4680401     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  32 in total

Review 1.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 3.  International variations and trends in renal cell carcinoma incidence and mortality.

Authors:  Ariana Znaor; Joannie Lortet-Tieulent; Mathieu Laversanne; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2014-10-16       Impact factor: 20.096

Review 4.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

5.  Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation.

Authors:  Seung Jin Lee; Eun Kyoung Yang; Sang Geon Kim
Journal:  Mol Pharmacol       Date:  2006-04-12       Impact factor: 4.436

6.  Roles of peroxisome proliferator-activated receptor-alpha and -gamma in the development of non-small cell lung cancer.

Authors:  Ming-Yue Li; Huiling Yuan; Lily T Ma; Angel W Y Kong; Michael K Y Hsin; Johnson H Y Yip; Malcolm J Underwood; George G Chen
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

7.  Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.

Authors:  Daisuke Nagata; Hashimoto Yoshihiro; Makoto Nakanishi; Hiromichi Naruyama; Shinsuke Okada; Ryosuke Ando; Keiichi Tozawa; Kenjiro Kohri
Journal:  Cancer Detect Prev       Date:  2008-09-11

8.  Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management.

Authors:  Kenji Yamazaki; Masahito Shimizu; Masataka Okuno; Rie Matsushima-Nishiwaki; Nobuhiro Kanemura; Hiroshi Araki; Hisashi Tsurumi; Soichi Kojima; I Bernard Weinstein; Hisataka Moriwaki
Journal:  Gut       Date:  2007-06-29       Impact factor: 23.059

9.  The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer.

Authors:  Farzad S Forootan; Shiva S Forootan; Mohammed I Malki; Danqing Chen; Gandi Li; Ke Lin; Philip S Rudland; Christopher S Foster; Youqiang Ke
Journal:  Int J Oncol       Date:  2013-11-05       Impact factor: 5.650

10.  Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis.

Authors:  Shuji Ogino; Kaori Shima; Yoshifumi Baba; Katsuhiko Nosho; Natsumi Irahara; Shoko Kure; Li Chen; Saori Toyoda; Gregory J Kirkner; Y Lynn Wang; Edward L Giovannucci; Charles S Fuchs
Journal:  Gastroenterology       Date:  2008-12-24       Impact factor: 33.883

View more
  9 in total

1.  A four-gene signature predicts survival in clear-cell renal-cell carcinoma.

Authors:  Jun Dai; Yuchao Lu; Jinyu Wang; Lili Yang; Yingyan Han; Ying Wang; Dan Yan; Qiurong Ruan; Shaogang Wang
Journal:  Oncotarget       Date:  2016-12-13

2.  In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself.

Authors:  Ines Breuksch; Jonas Welter; Heide-Katharina Bauer; Thorsten Enklaar; Sebastian Frees; Joachim W Thüroff; Annette Hasenburg; Dirk Prawitt; Walburgis Brenner
Journal:  Cell Commun Signal       Date:  2018-06-28       Impact factor: 5.712

3.  A panel of eight mRNA signatures improves prognosis prediction of osteosarcoma patients.

Authors:  Bo Wu; Zhan Wang; Nong Lin; Xiaobo Yan; Zhangchun Lv; Zhimin Ying; Zhaoming Ye
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

4.  Prognostic role of PHYH for overall survival (OS) in clear cell renal cell carcinoma (ccRCC).

Authors:  Qiu Zhengqi; Guo Zezhi; Jiang Lei; Qiu He; Pan Jinyao; Ao Ying
Journal:  Eur J Med Res       Date:  2021-01-19       Impact factor: 2.175

Review 5.  Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis.

Authors:  Lu Tang; Xintao Li; Yu Gao; Luyao Chen; Liangyou Gu; Jianwen Chen; Xiangjun Lyu; Yu Zhang; Xu Zhang
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

6.  Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma.

Authors:  Demin Fan; Qiang Liu; Fei Wu; Na Liu; Hongyi Qu; Yijiao Yuan; Yong Li; Huayu Gao; Juntao Ge; Yue Xu; Hao Wang; Qingyong Liu; Zuohui Zhao
Journal:  PeerJ       Date:  2020-06-01       Impact factor: 2.984

7.  PPARγ is dispensable for clear cell renal cell carcinoma progression.

Authors:  Danielle J Sanchez; David J Steger; Nicolas Skuli; Ankita Bansal; M Celeste Simon
Journal:  Mol Metab       Date:  2018-05-21       Impact factor: 7.422

8.  Free Fatty Acids Promote the Development of Prostate Cancer by Upregulating Peroxisome Proliferator-Activated Receptor Gamma.

Authors:  Xiaodan Ha; Jingzhou Wang; Cuizhe Wang; Keru Chen; Yuchun Deng; Xueting Zhang; Jiale Feng; Xue Li; Jiaojiao Zhu; Yinghua Ma; Tongtong Qiu; Jianxin Xie; Jun Zhang
Journal:  Cancer Manag Res       Date:  2020-02-24       Impact factor: 3.989

9.  PTEN: A Thrifty Gene That Causes Disease in Times of Plenty?

Authors:  Ajit Venniyoor
Journal:  Front Nutr       Date:  2020-06-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.